uPAR-PET/MRI in Patients With Prostate Cancer for Evaluation of Tumor Aggressiveness

• Status: Active, not recruiting
• Trial end date: 2022-04-01
• Target enrollment: 0
• Participant gender: Male

Summary

Prospective study to evaluate the value of uPAR-targeted PET/MR scan using the tracer 68Ga-NOTA-AE105 in patients with newly diagnosed prostate cancer

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rigshospitalet, Denmark

Criteria

Inclusion Criteria:

• Histologically verified prostate cancer

• Capable of understanding written information and giving informed consent

• Planned to enter active surveillance strategy or undergo therapy with curative intent (surgery or radiotherapy)

Exclusion Criteria:

• Obesity (Body weight over 140 kg)

• Known allergy to 68-Ga-NOTA-AE105

• Metallic components in the body that contradicts MRI scan

• Severe claustrophobia making the person unable to complete an MRI scan